News + Resources
Keep up with the latest
Featured
Recent
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
This Scientist Is Building Custom Gene-Editing Tools
November 11, 2024
This Scientist Is Building Custom Gene-Editing Tools
November 11, 2024
Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024
October 30, 2024
Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024
October 30, 2024
All Stories
News
Lilly Subsidiary, Scribe Ink Up-to-$1.5B CRISPR-Based Neuro Collaboration
May 16, 2023
Genetic Engineering & Biotechnology News
Read Now
Press
Lilly Subsidiary, Scribe Ink Up-to-$1.5B CRISPR-Based Neuro Collaboration
May 16, 2023
Genetic Engineering & Biotechnology News
Read Now
News
Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit
May 16, 2023
Fierce Biotech
Read Now
Press
Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit
May 16, 2023
Fierce Biotech
Read Now
News
Scribe pens $1.5B-plus CRISPR tech deal with Lilly
May 16, 2023
BioWorld
Read Now
Press
Scribe pens $1.5B-plus CRISPR tech deal with Lilly
May 16, 2023
BioWorld
Read Now
News
Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront cash/equity deal
May 16, 2023
Seeking Alpha
Read Now
Press
Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront cash/equity deal
May 16, 2023
Seeking Alpha
Read Now